Longitudinal study of interleukin-10, tumor necrosis factor-α, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease

Scandinavian Journal of Rheumatology

Volumn 30, Issue 5, 2001, Pages 282-289

  Hassan, A B ^a   Gunnarsson, I ^a   Karlsson, G ^a   Klareskog, L ^a   Forslid, J ^a   Lundberg, I E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti U1snRNP antibodies; IL 10; MCTD; SLAM; TNF

Indexed keywords

ANTIBODY; CYTOKINE; EPITOPE; INTERLEUKIN 10; SMALL NUCLEAR RIBONUCLEOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOLOGY; MALE; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-10; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034780490     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097401753180363     Document Type: Article

References (25)

1. Mixed connective tissue disease: An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
2. Autoantibodies to the URNP particles: Relationship to clinical diagnosis and nephritis
3. Histological evaluation of destructive monoarthropathy in mixed connective tissue disease
4. Association of antibodies to riboneucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases
5. Antinuclear antibodies. Diagnostic markers for autoimmune diseases and probes for cell biology
6. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients
7. Mixed connective tissue disease; A clinicopathologic study of 20 cases
8. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: A potential mechanism of B lymphocyte hyperactivity and autoimmunity
9. Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus
10. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: Lack of relationship with clinical disease activity
11. The roles of interleukin-6 and intereukin-10 in B cell hyperactivity in systemic lupus erythematosus
12. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families
13. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus
14. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus
15. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus
16. Increased serum levels of immunoglobulins, C-reactive protein, Type 1 and Type 2 cytokines in patients with mixed connective tissue disease
17. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
18. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus
19. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus
20. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients
21. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
22. Artifacts and limitations of enzyme immunoassay
23. Effects of bovine serum albumin on antibody determination by enzyme-linked immunosorbent assay
24. Monoclonal antibody two-site ELISA for human IFN-γ: Adaptation for determinations in human serum or plasma
25. Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serological findings